glp-1 drugs trump officials plan coverage for weight loss under Medicare and Medicaid | Trump administration The Trump Administration is delivering
Description
Clinical Frameworks: Defining Obesity Beyond Body Mass Index (BMI) An important milestone of 2025 was the publication of The Lancet Diabetes & Endocrinology Commission on the Definition and Diagnostic Criteria of Clinical Obesity
Glucagon-like peptide-1 (GLP-1) is an incretin peptide hormone mainly secreted by enteroendocrine intestinal L-cells
The Lilly glucagon-like peptide-1 receptor (GLP-1R) agonist ( LSN3318839 ) is a positive allosteric modulator intended to treat type 2 diabetes
While newly approved pharmacotherapies such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) show efficacy, their clinical utility remains constrained by dose-dependent gastrointestinal complications, underscoring the urgent need for safer alternatives
They are usually given as injections or pills
